Abstract
In prescription surveys, use of combination antipsychotics is common and is increasing, despite little supporting evidence. This article highlights potential problems with using combination antipsychotics, discusses paths to their maintenance use, and reviews the efficacy evidence. Paths to maintenance antipsychotic combinations include (1) failure or patient refusal of all reasonable monotherapies, (2) indefinite continuation of combinations initially intended to be brief, (3) trials of combinations in preference to reasonable monotherapy trials, and (4) addition of a second antipsychotic to counteract a problem (safety, tolerability, or adherence) arising during successful monotherapy. Virtually all of the evidence on combination antipsychotics is on augmentation of clozapine, with only one randomized controlled trial. Research on combination antipsychotics is sorely needed. Designing clinical trials is made difficult by the very large numbers of possible combinations and doses. It may be feasible to analyze existing data bases to identify combinations that appear particularly promising to investigate.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 105-109 |
| Number of pages | 5 |
| Journal | Schizophrenia Bulletin |
| Volume | 28 |
| Issue number | 1 |
| State | Published - 2002 |
Fingerprint
Keywords
- Antipsychotic agents
- Combination
- Drug therapy
- Polypharmacy
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Neuroscience(all)
Cite this
Combination antipsychotics : Pros, cons, and questions. / Miller, Alexander L; Craig, Catherine S.
In: Schizophrenia Bulletin, Vol. 28, No. 1, 2002, p. 105-109.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination antipsychotics
T2 - Pros, cons, and questions
AU - Miller, Alexander L
AU - Craig, Catherine S.
PY - 2002
Y1 - 2002
N2 - In prescription surveys, use of combination antipsychotics is common and is increasing, despite little supporting evidence. This article highlights potential problems with using combination antipsychotics, discusses paths to their maintenance use, and reviews the efficacy evidence. Paths to maintenance antipsychotic combinations include (1) failure or patient refusal of all reasonable monotherapies, (2) indefinite continuation of combinations initially intended to be brief, (3) trials of combinations in preference to reasonable monotherapy trials, and (4) addition of a second antipsychotic to counteract a problem (safety, tolerability, or adherence) arising during successful monotherapy. Virtually all of the evidence on combination antipsychotics is on augmentation of clozapine, with only one randomized controlled trial. Research on combination antipsychotics is sorely needed. Designing clinical trials is made difficult by the very large numbers of possible combinations and doses. It may be feasible to analyze existing data bases to identify combinations that appear particularly promising to investigate.
AB - In prescription surveys, use of combination antipsychotics is common and is increasing, despite little supporting evidence. This article highlights potential problems with using combination antipsychotics, discusses paths to their maintenance use, and reviews the efficacy evidence. Paths to maintenance antipsychotic combinations include (1) failure or patient refusal of all reasonable monotherapies, (2) indefinite continuation of combinations initially intended to be brief, (3) trials of combinations in preference to reasonable monotherapy trials, and (4) addition of a second antipsychotic to counteract a problem (safety, tolerability, or adherence) arising during successful monotherapy. Virtually all of the evidence on combination antipsychotics is on augmentation of clozapine, with only one randomized controlled trial. Research on combination antipsychotics is sorely needed. Designing clinical trials is made difficult by the very large numbers of possible combinations and doses. It may be feasible to analyze existing data bases to identify combinations that appear particularly promising to investigate.
KW - Antipsychotic agents
KW - Combination
KW - Drug therapy
KW - Polypharmacy
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=0035988577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035988577&partnerID=8YFLogxK
M3 - Article
C2 - 12047009
AN - SCOPUS:0035988577
VL - 28
SP - 105
EP - 109
JO - Schizophrenia Bulletin
JF - Schizophrenia Bulletin
SN - 0586-7614
IS - 1
ER -